Rejection (Psychology)
Zealand’s Hypoglycemia Drug Faces Second FDA Rejection Due to Manufacturing Issues
Zealand Pharma, FDA rejection, dasiglucagon, congenital hyperinsulinism, hypoglycemia, CDMO inspection
Vanda Pharmaceuticals Receives FDA Rejection for Gastroparesis Treatment, Criticizes Agency’s Decision
Vanda Pharmaceuticals, FDA rejection, gastroparesis treatment, tradipitant, conclusory refusal
Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection
Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection
FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer
Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
FDA’s Rejection of Lykos’ MDMA-Assisted Therapy for PTSD: A Setback but Not a Roadblock for Psychedelic Research
MDMA, PTSD, Lykos Therapeutics, FDA rejection, psychedelic therapy, clinical trials, ethical violations, scientific integrity.
Novo Nordisk’s Once-Weekly Insulin Icodec Faces FDA Rejection and Manufacturing Concerns
Novo Nordisk, icodec, FDA rejection, once-weekly insulin, manufacturing issues, type 1 diabetes, type 2 diabetes, semaglutide, IcoSema
Lykos Faces Significant Setbacks as FDA Rejects MDMA Therapy and Three Studies Are Retracted Due to Unethical Conduct
Lykos Therapeutics, MDMA therapy, FDA rejection, study retractions, unethical conduct, PTSD treatment, psychedelic research
Aldeyra’s Reproxalap Demonstrates Efficacy in Reducing Eye Discomfort in New Phase 3 Study
Aldeyra Therapeutics, Reproxalap, Phase 3 Study, Eye Discomfort, Dry Eye Disease, FDA Rejection
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection